FOLFIRI-话题@MedSci

#FOLFIRI#

27篇内容 | 1929人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2183025, encodeId=0edb2183025f6, content=<a href='/topic/show?id=0a9e922085f' target=_blank style='color:#2F92EE;'>#贝伐珠单抗#</a> <a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a> <a href='/topic/show?id=aaea1339031' target=_blank style='color:#2F92EE;'>#Onvansertib#</a>, objectTitle=Clin. Cancer Res：Onvansertib联合FOLFIRI和贝伐珠单抗二线治疗KRAS突变转移性结直肠癌：1b期临床研究, objectType=article, longId=810272, objectId=4c308102e293, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240120/1705756753241_6145188.jpg, objectUrl=/article/show_article.do?id=4c308102e293, replyNumber=0, likeNumber=129, createdTime=2024-01-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4c308102e293, moduleTitle=Clin. Cancer Res：Onvansertib联合FOLFIRI和贝伐珠单抗二线治疗KRAS突变转移性结直肠癌：1b期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c308102e293)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1478149, encodeId=090314e8149df, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, objectTitle=JAMA Oncol：术后采用改良的FOLFIRINOX方案辅助治疗可显著延长胰腺导管腺癌患者的长期预后, objectType=article, longId=738555, objectId=c150e3855510, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c150e3855510, replyNumber=0, likeNumber=109, createdTime=2022-09-09, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c150e3855510, moduleTitle=JAMA Oncol：术后采用改良的FOLFIRINOX方案辅助治疗可显著延长胰腺导管腺癌患者的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c150e3855510)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478148, encodeId=f92514e814880, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, objectTitle=Clin Oncol：FOLFIRI联合贝伐珠单抗对比FOLFIRI联合阿柏西普二线治疗转移性结直肠癌的疗效, objectType=article, longId=301244, objectId=cf6f3012449f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf6f3012449f, replyNumber=0, likeNumber=113, createdTime=2022-03-22, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf6f3012449f, moduleTitle=Clin Oncol：FOLFIRI联合贝伐珠单抗对比FOLFIRI联合阿柏西普二线治疗转移性结直肠癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf6f3012449f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478147, encodeId=bddb14e81476c, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, objectTitle=Ther Adv Med Oncol：国内多中心头对头III期研究发现转移性结直肠癌患者二线FOLFIRI方案并不优于单药伊立替康治疗，反而毒性增加, objectType=article, longId=294046, objectId=01c32940469c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01c32940469c, replyNumber=0, likeNumber=130, createdTime=2022-01-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01c32940469c, moduleTitle=Ther Adv Med Oncol：国内多中心头对头III期研究发现转移性结直肠癌患者二线FOLFIRI方案并不优于单药伊立替康治疗，反而毒性增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01c32940469c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478146, encodeId=054c14e81463b, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, objectTitle=Ther Adv Med Oncol：在FOLFIRINOX治疗失败的晚期胰腺癌患者中，GnP（吉西他滨+白蛋白结合型紫杉醇）是可行的治疗措施, objectType=article, longId=293056, objectId=308a29305649, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=308a29305649, replyNumber=0, likeNumber=103, createdTime=2021-12-30, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=308a29305649, moduleTitle=Ther Adv Med Oncol：在FOLFIRINOX治疗失败的晚期胰腺癌患者中，GnP（吉西他滨+白蛋白结合型紫杉醇）是可行的治疗措施, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=308a29305649)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478145, encodeId=5ee514e814559, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, objectTitle=Clin Cancer Res：PARP抑制剂Veliparib联合优化的FOLFIRI作为二线治疗转移性胰腺癌, objectType=article, longId=221813, objectId=789422181362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=789422181362, replyNumber=0, likeNumber=135, createdTime=2021-12-11, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=789422181362, moduleTitle=Clin Cancer Res：PARP抑制剂Veliparib联合优化的FOLFIRI作为二线治疗转移性胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=789422181362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478144, encodeId=d23414e814400, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, objectTitle=ESMO Open：Nab-紫杉醇/吉西他滨和FOLFIRINOX作为一线序贯治疗转移性胰腺癌, objectType=article, longId=221332, objectId=bde422133214, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bde422133214, replyNumber=0, likeNumber=93, createdTime=2021-12-01, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bde422133214, moduleTitle=ESMO Open：Nab-紫杉醇/吉西他滨和FOLFIRINOX作为一线序贯治疗转移性胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bde422133214)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478143, encodeId=7a0014e814377, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, objectTitle=西妥昔单抗联合FOLFIRI 双周方案在野生型K．Ras 基因晚期结直肠癌患者中的Ⅱ期临床观察, objectType=article, longId=220892, objectId=769f22089252, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=769f22089252, replyNumber=0, likeNumber=89, createdTime=2021-11-25, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=769f22089252, moduleTitle=西妥昔单抗联合FOLFIRI 双周方案在野生型K．Ras 基因晚期结直肠癌患者中的Ⅱ期临床观察, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=769f22089252)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478142, encodeId=5a0c14e8142f8, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, objectTitle=Eur J Cancer：3期| 改良版FOLFIRINOX vs S-1方案二线治疗吉西他滨难治性转移性胰腺癌的疗效, objectType=article, longId=216768, objectId=ddae216e6887, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddae216e6887, replyNumber=0, likeNumber=99, createdTime=2021-09-08, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddae216e6887, moduleTitle=Eur J Cancer：3期| 改良版FOLFIRINOX vs S-1方案二线治疗吉西他滨难治性转移性胰腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddae216e6887)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478141, encodeId=a4a214e81417e, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, objectTitle=Eur J Cancer：吉西他滨+白蛋白结合型紫杉醇对比FOLFIRINOX一线治疗晚期胰腺癌疗效和安全性, objectType=article, longId=211073, objectId=73fa2110e321, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73fa2110e321, replyNumber=0, likeNumber=150, createdTime=2021-05-12, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73fa2110e321, moduleTitle=Eur J Cancer：吉西他滨+白蛋白结合型紫杉醇对比FOLFIRINOX一线治疗晚期胰腺癌疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73fa2110e321)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478140, encodeId=4e1414e81403e, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, objectTitle=Lancet Gastroenterol Hepatol：晚期胰腺癌的术前诱导化疗 Nab-紫杉醇+吉西他滨是否需继以FOLFIRINOX序贯化疗？, objectType=article, longId=204661, objectId=1ee920466151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ee920466151, replyNumber=0, likeNumber=89, createdTime=2020-12-20, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ee920466151, moduleTitle=Lancet Gastroenterol Hepatol：晚期胰腺癌的术前诱导化疗 Nab-紫杉醇+吉西他滨是否需继以FOLFIRINOX序贯化疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ee920466151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478139, encodeId=755c14e8139d7, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, objectTitle=Br J Cancer：FOLFIRI治疗方案与西妥昔单抗或贝伐单抗联合治疗晚期结直肠癌的FIRE-3 3期随机临床研究, objectType=article, longId=203464, objectId=b4f620346485, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4f620346485, replyNumber=0, likeNumber=104, createdTime=2020-11-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4f620346485, moduleTitle=Br J Cancer：FOLFIRI治疗方案与西妥昔单抗或贝伐单抗联合治疗晚期结直肠癌的FIRE-3 3期随机临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4f620346485)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478138, encodeId=7a9a14e81386f, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, objectTitle=JAMA Surg：FOLFIRINOX或GA方案一线治疗局限性胰腺导管腺癌, objectType=article, longId=197882, objectId=db4319e88233, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db4319e88233, replyNumber=0, likeNumber=105, createdTime=2020-07-23, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db4319e88233, moduleTitle=JAMA Surg：FOLFIRINOX或GA方案一线治疗局限性胰腺导管腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db4319e88233)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478137, encodeId=1a9914e8137c0, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, objectTitle=Lancet oncol：3期试验：FOLFOXIRI+贝伐珠单抗预治疗/再治疗转移性结直肠癌的效果优于mFOLFOX6+贝伐单抗/FOLFIRI+贝伐单抗, objectType=article, longId=190232, objectId=9131190232f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9131190232f7, replyNumber=0, likeNumber=90, createdTime=2020-03-19, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9131190232f7, moduleTitle=Lancet oncol：3期试验：FOLFOXIRI+贝伐珠单抗预治疗/再治疗转移性结直肠癌的效果优于mFOLFOX6+贝伐单抗/FOLFIRI+贝伐单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9131190232f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478136, encodeId=4b4514e8136a7, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, objectTitle=NMPA批准默克的EGFR单抗西妥昔联合FOLFOX或FOLFIRI化疗，用于国内RAS野生型转移性结直肠癌患者的一线治疗, objectType=article, longId=180183, objectId=e8d718018362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8d718018362, replyNumber=0, likeNumber=83, createdTime=2019-09-29, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8d718018362, moduleTitle=NMPA批准默克的EGFR单抗西妥昔联合FOLFOX或FOLFIRI化疗，用于国内RAS野生型转移性结直肠癌患者的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8d718018362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478135, encodeId=6b2d14e8135ae, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, objectTitle=NEJM：胰腺癌辅助治疗：FOLFIRINOX方案pk吉西他滨, objectType=article, longId=158718, objectId=d507158e1853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d507158e1853, replyNumber=0, likeNumber=131, createdTime=2019-01-25, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d507158e1853, moduleTitle=NEJM：胰腺癌辅助治疗：FOLFIRINOX方案pk吉西他滨, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d507158e1853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478134, encodeId=432714e813403, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, objectTitle=CLIN CANCER RES：DNA损伤修复基因突变与接受FOLFIRINOX治疗的胰腺导管癌患者预后改善有关, objectType=article, longId=156364, objectId=7f2a1563646d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f2a1563646d, replyNumber=0, likeNumber=149, createdTime=2018-12-23, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f2a1563646d, moduleTitle=CLIN CANCER RES：DNA损伤修复基因突变与接受FOLFIRINOX治疗的胰腺导管癌患者预后改善有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f2a1563646d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478133, encodeId=846d14e81336b, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, objectTitle=CLIN CANCER RES：Duligotuzumab联合FOLFIRI方案治疗RAS野生型转移性结直肠癌, objectType=article, longId=139634, objectId=060d13963424, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=060d13963424, replyNumber=0, likeNumber=131, createdTime=2018-06-02, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=060d13963424, moduleTitle=CLIN CANCER RES：Duligotuzumab联合FOLFIRI方案治疗RAS野生型转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=060d13963424)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478132, encodeId=b07914e81325d, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, objectTitle=Lancet oncol：mXELIRI或许可以替换FOLFIRI作为转移性结直肠癌的标准二线疗法, objectType=article, longId=132833, objectId=67b213283312, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67b213283312, replyNumber=0, likeNumber=82, createdTime=2018-03-20, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67b213283312, moduleTitle=Lancet oncol：mXELIRI或许可以替换FOLFIRI作为转移性结直肠癌的标准二线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67b213283312)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478131, encodeId=6ccb14e8131e5, content=<a href='/topic/show?id=0529e56859' target=_blank style='color:#2F92EE;'>#FOLFIRI#</a>, objectTitle=EUR J Cancer：转移性结直肠癌治疗中，BRAF和RAS突变对一线疗法（FOLFIRI加西妥昔单抗，FOLFIRI加贝伐单抗）的影响, objectType=article, longId=125177, objectId=1e501251e7c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e501251e7c5, replyNumber=0, likeNumber=137, createdTime=2018-01-01, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e501251e7c5, moduleTitle=EUR J Cancer：转移性结直肠癌治疗中，BRAF和RAS突变对一线疗法（FOLFIRI加西妥昔单抗，FOLFIRI加贝伐单抗）的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e501251e7c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FOLFIRI

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#贝伐珠单抗# #FOLFIRI# #Onvansertib#

Clin. Cancer Res：Onvansertib联合FOLFIRI和贝伐珠单抗二线治疗KRAS突变转移性结直肠癌：1b期临床研究

2024-01-21发表于上海

仁者大医 (审核中...)

前往app查看评论内容

#FOLFIRI#

JAMA Oncol：术后采用改良的FOLFIRINOX方案辅助治疗可显著延长胰腺导管腺癌患者的长期预后

2022-09-09

仁者大医 (审核中...)

前往app查看评论内容

#FOLFIRI#

Clin Oncol：FOLFIRI联合贝伐珠单抗对比FOLFIRI联合阿柏西普二线治疗转移性结直肠癌的疗效

2022-03-22

仁者大医 (审核中...)

前往app查看评论内容

#FOLFIRI#

Ther Adv Med Oncol：国内多中心头对头III期研究发现转移性结直肠癌患者二线FOLFIRI方案并不优于单药伊立替康治疗，反而毒性增加

2022-01-17

仁者大医 (审核中...)

前往app查看评论内容

#FOLFIRI#

Ther Adv Med Oncol：在FOLFIRINOX治疗失败的晚期胰腺癌患者中，GnP（吉西他滨+白蛋白结合型紫杉醇）是可行的治疗措施

2021-12-30

仁者大医 (审核中...)

前往app查看评论内容

#FOLFIRI#

Clin Cancer Res：PARP抑制剂Veliparib联合优化的FOLFIRI作为二线治疗转移性胰腺癌

2021-12-11

仁者大医 (审核中...)

前往app查看评论内容

#FOLFIRI#

ESMO Open：Nab-紫杉醇/吉西他滨和FOLFIRINOX作为一线序贯治疗转移性胰腺癌

2021-12-01

仁者大医 (审核中...)

前往app查看评论内容

#FOLFIRI#

西妥昔单抗联合FOLFIRI 双周方案在野生型K．Ras 基因晚期结直肠癌患者中的Ⅱ期临床观察

2021-11-25

仁者大医 (审核中...)

前往app查看评论内容

#FOLFIRI#

Eur J Cancer：3期| 改良版FOLFIRINOX vs S-1方案二线治疗吉西他滨难治性转移性胰腺癌的疗效

2021-09-08

仁者大医 (审核中...)

前往app查看评论内容

#FOLFIRI#

Eur J Cancer：吉西他滨+白蛋白结合型紫杉醇对比FOLFIRINOX一线治疗晚期胰腺癌疗效和安全性

2021-05-12

仁者大医 (审核中...)

前往app查看评论内容

#FOLFIRI#

Lancet Gastroenterol Hepatol：晚期胰腺癌的术前诱导化疗 Nab-紫杉醇+吉西他滨是否需继以FOLFIRINOX序贯化疗？

2020-12-20

仁者大医 (审核中...)

前往app查看评论内容

#FOLFIRI#

Br J Cancer：FOLFIRI治疗方案与西妥昔单抗或贝伐单抗联合治疗晚期结直肠癌的FIRE-3 3期随机临床研究

2020-11-17

仁者大医 (审核中...)

前往app查看评论内容

#FOLFIRI#

JAMA Surg：FOLFIRINOX或GA方案一线治疗局限性胰腺导管腺癌

2020-07-23

仁者大医 (审核中...)

前往app查看评论内容

#FOLFIRI#

Lancet oncol：3期试验：FOLFOXIRI+贝伐珠单抗预治疗/再治疗转移性结直肠癌的效果优于mFOLFOX6+贝伐单抗/FOLFIRI+贝伐单抗

2020-03-19

仁者大医 (审核中...)

前往app查看评论内容

#FOLFIRI#

NMPA批准默克的EGFR单抗西妥昔联合FOLFOX或FOLFIRI化疗，用于国内RAS野生型转移性结直肠癌患者的一线治疗

2019-09-29

仁者大医 (审核中...)

前往app查看评论内容

#FOLFIRI#

NEJM：胰腺癌辅助治疗：FOLFIRINOX方案pk吉西他滨

2019-01-25

仁者大医 (审核中...)

前往app查看评论内容

#FOLFIRI#

CLIN CANCER RES：DNA损伤修复基因突变与接受FOLFIRINOX治疗的胰腺导管癌患者预后改善有关

2018-12-23

仁者大医 (审核中...)

前往app查看评论内容

#FOLFIRI#

CLIN CANCER RES：Duligotuzumab联合FOLFIRI方案治疗RAS野生型转移性结直肠癌

2018-06-02

仁者大医 (审核中...)

前往app查看评论内容

#FOLFIRI#

Lancet oncol：mXELIRI或许可以替换FOLFIRI作为转移性结直肠癌的标准二线疗法

2018-03-20

仁者大医 (审核中...)

前往app查看评论内容

#FOLFIRI#

EUR J Cancer：转移性结直肠癌治疗中，BRAF和RAS突变对一线疗法（FOLFIRI加西妥昔单抗，FOLFIRI加贝伐单抗）的影响

2018-01-01

科室
- - 订阅+
  - 更多科室
工具
服务